Wellbeing Subsidiary KGK Science Announces Successful Delivery of CBD and THC Through the Skin of Healthy Volunteers

VANCOUVER, British Columbia--(BUSINESS WIRE)--Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announced today that its wholly owned subsidiary KGK Science Inc. (“KGK”), completed an open label study, where Gefion Canada (“Gefion”) GT4 technology was used to successfully deliver cannabidiol (CBD) and tetrahydrocannabinol (THC) to healthy volunteers in the form of a topical cream applied to the skin. Gefion GT4 technology uses novel penetrating agents to transport CBD and THC through the skin and directly into the blood. Transdermal delivery of topically-applied cannabinoids can be difficult and prior to this study, published research demonstrating successful topical delivery did not exist. The Gefion Canada study, published in Advances in Therapy, showed for the first time that CBD and THC were successfully transported into the blood stream following application to the skin. Gefion GT4 technology may provide lower, more steady-state cannabinoid concentrations that minimize psychoactive effects in participants. These findings present a potential benefit in the treatment of chronic conditions over longer periods of time, or in the treatment of diseases where high concentrations of cannabinoids are needed in relation to the body weight of vulnerable populations such as pediatrics. Importantly, CBD and THC delivery in this study was found to be safe and well tolerated by all participants. None of the volunteers experienced any intoxicating effects. Topical cannabis may provide the benefit of extended cannabinoid delivery without the worry of intoxication, suggesting it may be beneficial for certain lifestyles and therapeutic indications. However, more research is needed. “This study represents an important step forward in cannabis research. This study opens the door for future double-blind, placebo-controlled trials to further investigate topical cannabis delivery,” says Dr. Erin D. Lewis, Scientific Director at KGK Science. ABOUT GEFION Gefion is a specialty pharmaceutical company whose mission is to utilize its technological, regulatory and commercial advantages to market cannabinoid prescription products in the United States, Canada and Europe focusing on established markets with predicate products and insurance reimbursement. It is developing GT4 CBD for the treatment of epilepsy in children. ABOUT KGK SCIENCE Subsidiary of Wellbeing Digital Sciences, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products. Founded in 1997, the business has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. Furthermore, the company has produced over 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database and collected 10 million data points. For additional information, please visit kgkscience.com. ABOUT WELLBEING DIGITAL SCIENCES
http://dlvr.it/SclVQg